Aspen Neuroscience, a clinical-stage regenerative medicine biotechnology company, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for sasineprocel (ANPD001), its lead investigational autologous cell therapy for the treatment of Parkinson's Disease (PD). The designation is expected to accelerate the therapy's clinical development and regulatory review while strengthening the company's efforts to address a significant unmet need in neurodegenerative disease.

The RMAT designation provides enhanced FDA guidance throughout development, including early and frequent regulatory interactions and potential eligibility for priority review and accelerated approval pathways for regenerative medicine products. Sasineprocel had previously received FDA Fast Track designation, further highlighting its potential as a disease-modifying treatment for Parkinson's disease.

The FDA's decision is supported by encouraging data from the ongoing Phase 1/2a ASPIRO trial, which has demonstrated an encouraging safety profile and early signs of clinical activity. The multicentre, open-label study is evaluating the safety, tolerability and therapeutic potential of surgically delivering autologous Dopaminergic Neuron Precursor Cells (DANPCs) into the putamen, the region of the brain responsible for dopamine signalling that is progressively affected in Parkinson's disease.

Damien McDevitt, President and Chief Executive Officer of Aspen Neuroscience, said the RMAT designation recognises the transformative potential of sasineprocel as a therapy capable of modifying disease progression in patients living with Parkinson's disease. He added that the company remains committed to advancing the programme as quickly as possible to address the growing unmet medical need.

Ana Sousa, Chief Regulatory Officer at Aspen Neuroscience, noted that the RMAT programme provides a collaborative regulatory framework designed to streamline development through closer interaction with the FDA. She said the company continues to advance the investigational therapy with the goal of regenerating neural networks, restoring lost neuronal function, improving motor performance and potentially slowing or reversing disease progression.

Sasineprocel is a single-dose, autologous induced Pluripotent Stem Cell (iPSC)-based therapy developed using a patient's own skin cells. The cells are collected through a small skin biopsy, reprogrammed into induced pluripotent stem cells and differentiated into dopaminergic neuron precursor cells before being transplanted into the patient's brain using image-guided delivery.

The therapy is designed to replace dopamine-producing neurons lost during Parkinson's disease progression while rebuilding damaged neural circuitry. By creating a biologically active cellular environment that supports cell survival and functional integration, the treatment aims to deliver durable clinical benefits and potentially alter the course of the disease.

Because sasineprocel uses the patient's own cells, the therapy eliminates the need for immunosuppressive treatment typically required with donor-derived (allogeneic) cell therapies, potentially improving long-term safety and tolerability.

The RMAT designation was established under the 21st Century Cures Act to accelerate the development and review of regenerative medicine therapies intended to treat, modify, reverse or cure serious diseases. Products receiving the designation must demonstrate preliminary clinical evidence indicating their potential to address unmet medical needs.

Aspen Neuroscience is focused on developing personalised, autologous iPSC-derived regenerative therapies, with an initial emphasis on Parkinson's disease and other neurodegenerative disorders where effective disease-modifying treatments remain limited.